Infection control knowledge, beliefs and behaviours amongst cystic fibrosis patients with epidemic Pseudomonas aeruginosa

BMC Pulmonary Medicine

Volumn 15, Issue 1, 2015, Pages

  Somayaji, R ^a   Waddell, B ^b   Workentine, M L ^b   Surette, M G ^b,c,d   Brager, N P ^a   Rabin, H R ^a,b   Parkins, M D ^a,b  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

Author keywords

Infection transmission; Liverpool epidemic strain; Prairie epidemic strain; Transmissible strains

Indexed keywords

ADULT; ARTICLE; BACTERIAL TRANSMISSION; BACTERIUM ISOLATE; COHORT ANALYSIS; CONTROLLED STUDY; CYSTIC FIBROSIS; DISEASE ASSOCIATION; EPIDEMIC; FEMALE; HEALTH BEHAVIOR; HEALTH BELIEF; HUMAN; INFECTION CONTROL; INFECTION RISK; INTERPERSONAL COMMUNICATION; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIUM; PATIENT ATTITUDE; PEER REVIEW; PROSPECTIVE STUDY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RETROSPECTIVE STUDY; RISK ASSESSMENT; SOCIAL INTERACTION; SOCIAL SUPPORT; STAPHYLOCOCCUS AUREUS; ATTITUDE TO HEALTH; ATYPICAL MYCOBACTERIUM; COINFECTION; MICROBIOLOGY; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; PEER GROUP; PSEUDOMONAS INFECTIONS; PSYCHOLOGY; RISK FACTOR; STAPHYLOCOCCAL INFECTIONS; YOUNG ADULT;

ADULT; COINFECTION; CYSTIC FIBROSIS; EPIDEMICS; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; INFECTION CONTROL; MALE; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; NONTUBERCULOUS MYCOBACTERIA; PEER GROUP; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RETROSPECTIVE STUDIES; RISK FACTORS; SOCIAL SUPPORT; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; YOUNG ADULT;

EID: 84959254177     PISSN: None     EISSN: 14712466     Source Type: Journal    
DOI: 10.1186/s12890-015-0116-x     Document Type: Article

References (38)

1. Cheng K, Smyth RL, Govan JR, Doherty C, Winstanley C, Denning N, et al. Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic. Lancet. 1996;348(9028):639-42.
2. Aaron SD, Vandemheen KL, Ramotar K, Giesbrecht-Lewis T, Tullis E, Freitag A, et al. Infection with transmissible strains of Pseudomonas aeruginosa and clinical outcomes in adults with cystic fibrosis. JAMA. 2010;304(19):2145-53.
3. Scott FW, Pitt TL. Identification and characterization of transmissible Pseudomonas aeruginosa strains in cystic fibrosis patients in England and Wales. J Med Microbiol. 2004;53(Pt 7):609-15.
4. Martin K, Baddal B, Mustafa N, Perry C, Underwood A, Constantidou C, et al. Clusters of genetically similar isolates of Pseudomonas aeruginosa from multiple hospitals in the UK. J Med Microbiol. 2013;62(Pt 7):988-1000.
5. Ashish A, Shaw M, Winstanley C, Ledson MJ, Walshaw MJ. Increasing resistance of the Liverpool Epidemic Strain (LES) of Pseudomonas aeruginosa (Psa) to antibiotics in cystic fibrosis (CF)--a cause for concern? J Cyst Fibros. 2012;11(3):173-9.
6. Armstrong DS, Nixon GM, Carzino R, Bigham A, Carlin JB, Robins-Browne RM, et al. Detection of a widespread clone of Pseudomonas aeruginosa in a pediatric cystic fibrosis clinic. Am J Respir Crit Care Med. 2002;166(7):983-7.
7. Parkins MD, Glezerson BA, Sibley CD, Sibley KA, Duong J, Purighalla S, et al. Twenty-five-year outbreak of Pseudomonas aeruginosa infecting individuals with cystic fibrosis: identification of the prairie epidemic strain. J Clin Microbiol. 2014;52(4):1127-35.
8. O'Carroll MR, Syrmis MW, Wainwright CE, Greer RM, Mitchell P, Coulter C, et al. Clonal strains of Pseudomonas aeruginosa in paediatric and adult cystic fibrosis units. Eur Respir J. 2004;24(1):101-6.
9. Fothergill JL, Walshaw MJ, Winstanley C. Transmissible strains of Pseudomonas aeruginosa in cystic fibrosis lung infections. Eur Respir J. 2012;40(1):227-38.
10. Al-Aloul M, Crawley J, Winstanley C, Hart CA, Ledson MJ, Walshaw MJ. Increased morbidity associated with chronic infection by an epidemic Pseudomonas aeruginosa strain in CF patients. Thorax. 2004;59(4):334-6.
11. Jones AM, Dodd ME, Morris J, Doherty C, Govan JR, Webb AK. Clinical outcome for cystic fibrosis patients infected with transmissible pseudomonas aeruginosa: an 8-year prospective study. Chest. 2010;137(6):1405-9.
12. Poonja A, Workentine, M, Waddell, B, Surette, MG, Duong, J, DG Storey, Gregson, D, Rabin, HR and MD Parkins. Development and validation of a PCR assay to detect the Prairie Epidemic Strain (PES) of Pseudomonas aeruginosa. In. Ped Pulmonol: 2015; Phoenix, AZ; 2015.
13. Somayaji RLJ, Surette M, Waddell B, Purighalla S, Sibley C, Rabin H, et al. Clinical outcomes of chronic 'Prairie Epidemic Strain' Pseudomonas aeruginosa infection in adults with cystic fibrosis. In: 38th Annual European Cystic Fibrosis Conference. Brussels: Journal of Cystic Fibrosis; 2015. 2015.
14. Masterson TL, Wildman BG, Newberry BH, Omlor GJ. Impact of age and gender on adherence to infection control guidelines and medical regimens in cystic fibrosis. Pediatr Pulmonol. 2011;46(3):295-301.
15. Sibley CD, Sibley KA, Leong TA, Grinwis ME, Parkins MD, Rabin HR, et al. The Streptococcus milleri population of a cystic fibrosis clinic reveals patient specificity and intraspecies diversity. J Clin Microbiol. 2010;48(7):2592-4.
16. Lee TW, Brownlee KG, Conway SP, Denton M, Littlewood JM. Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J Cyst Fibros. 2003;2(1):29-34.
17. Walter S, Gudowius P, Bosshammer J, Romling U, Weissbrodt H, Schurmann W, et al. Epidemiology of chronic Pseudomonas aeruginosa infections in the airways of lung transplant recipients with cystic fibrosis. Thorax. 1997;52(4):318-21.
18. Varekojis SM, Douce FH, Flucke RL, Filbrun DA, Tice JS, McCoy KS, et al. A comparison of the therapeutic effectiveness of and preference for postural drainage and percussion, intrapulmonary percussive ventilation, and high-frequency chest wall compression in hospitalized cystic fibrosis patients. Respir Care. 2003;48(1):24-8.
19. Saint S, Greene MT, Olmsted RN, Chopra V, Meddings J, Safdar N, et al. Perceived strength of evidence supporting practices to prevent health care-associated infection: results from a national survey of infection prevention personnel. Am J Infect Control. 2013;41(2):100-6.
20. Tummler B, Koopmann U, Grothues D, Weissbrodt H, Steinkamp G, von der Hardt H. Nosocomial acquisition of Pseudomonas aeruginosa by cystic fibrosis patients. J Clin Microbiol. 1991;29(6):1265-7.
21. Ojeniyi B, Frederiksen B, Hoiby N. Pseudomonas aeruginosa cross-infection among patients with cystic fibrosis during a winter camp. Pediatr Pulmonol. 2000;29(3):177-81.
22. Walsh NM, Casano AA, Manangan LP, Sinkowitz-Cochran RL, Jarvis WR. Risk factors for Burkholderia cepacia complex colonization and infection among patients with cystic fibrosis. J Pediatr. 2002;141(4):512-7.
23. Razvi S, Quittell L, DiMango E, Andersen J, Sewell W, Garber E, et al. Abstract 348: CF patients and families' perspectives of infection control recommendations. Pediatr Pulmonol. 2006;S29(S29):329-30.
24. Miroballi Y, Garber E, Jia H, Zhou JJ, Alba L, Quittell LM, et al. Infection control knowledge, attitudes, and practices among cystic fibrosis patients and their families. Pediatr Pulmonol. 2012;47(2):144-52.
25. Clifton IJ, Peckham DG. Defining routes of airborne transmission of Pseudomonas aeruginosa in people with cystic fibrosis. Expert Rev Respir Med. 2010;4(4):519-29.
26. Zimakoff J, Hoiby N, Rosendal K, Guilbert JP. Epidemiology of Pseudomonas aeruginosa infection and the role of contamination of the environment in a cystic fibrosis clinic. J Hosp Infect. 1983;4(1):31-40.
27. Wainwright CE, France MW, O'Rourke P, Anuj S, Kidd TJ, Nissen MD, et al. Cough-generated aerosols of Pseudomonas aeruginosa and other Gram-negative bacteria from patients with cystic fibrosis. Thorax. 2009;64(11):926-31.
28. Saiman L, Siegel JD, LiPuma JJ, Brown RF, Bryson EA, Chambers MJ, et al. Infection prevention and control guideline for cystic fibrosis: 2013 update. Infect Control Hosp Epidemiol. 2014;35 Suppl 1:S1-S67.
29. Zuckerman JB, Clock SA, Prato BS, McDevitt JJ, Zhou JJ, Leclair LW, et al. Air contamination with bacteria in cystic fibrosis clinics: implications for prevention strategies. Am J Respir Crit Care Med. 2015;191(5):598-601.
30. Ashish A, Shaw M, Winstanley C, Humphreys L, Walshaw MJ. Halting the spread of epidemic pseudomonas aeruginosa in an adult cystic fibrosis centre: a prospective cohort study. JRSM Short Rep. 2013;4(1):1.
31. Griffiths AL, Jamsen K, Carlin JB, Grimwood K, Carzino R, Robinson PJ, et al. Effects of segregation on an epidemic Pseudomonas aeruginosa strain in a cystic fibrosis clinic. Am J Respir Crit Care Med. 2005;171(9):1020-5.
32. Matt B, Mitteregger D, Renner S, Presterl E, Assadian O, Diab-Elschahawi M. Successful implementation of infection control strategies prevents P. aeruginosa transmission among cystic fibrosis patients inside the hospital. GMS hygiene and infection control. 2014;9(3):Doc20.
33. Saiman L, Garber E. Infection control in cystic fibrosis: barriers to implementation and ideas for improvement. Curr Opin Pulm Med. 2009;15(6):626-31.
34. Jones AM, Dodd ME, Govan JR, Doherty CJ, Smith CM, Isalska BJ, et al. Prospective surveillance for Pseudomonas aeruginosa cross-infection at a cystic fibrosis center. Am J Respir Crit Care Med. 2005;171(3):257-60.
35. McCallum SJ, Corkill J, Gallagher M, Ledson MJ, Hart CA, Walshaw MJ. Superinfection with a transmissible strain of Pseudomonas aeruginosa in adults with cystic fibrosis chronically colonised by P aeruginosa. Lancet. 2001;358(9281):558-60.
36. Garber E, Desai M, Zhou J, Alba L, Angst D, Cabana M, et al. Barriers to adherence to cystic fibrosis infection control guidelines. Pediatr Pulmonol. 2008;43(9):900-7.
37. MY CF CANADA NETWORK [ http://www.mycfnetwork.com ]
38. Kirk S, Milnes L. An exploration of how young people and parents use online support in the context of living with cystic fibrosis. Health Expectations. 2015. doi: 10.1111/hex.12352. [Epub ahead of print].